SCHEMBL17273902

SCHEMBL17273902

O=C(O)c1ccccc1-c1ccccc1C(=O)Nc1ccc2c(c1)[nH]c(=O)c1ccccc12.c1ccc(-c2ccc3c(c2)N[C@@H]([C@H]2Nc4cc(-c5ccccc5)ccc4O2)O3)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 6/20 0.70
▸ MEN1 O00255 5/20 0.70
▸ KDM4E B2RXH2 3/20 0.70
▸ CYP2C9 P11712 3/20 0.70
▸ CYP3A4 P08684 2/20 0.70
▸ TDP1 Q9NUW8 2/20 0.70
▸ CYP1A2 P05177 1/20 0.70
▸ GAA P10253 1/20 0.45
▸ BRD4 O60885 2/20 0.41
▸ LMNA P02545 1/20 0.39
▸ POLB P06746 2/20 0.39
▸ MAPT P10636 2/20 0.39
▸ ALOX12 P18054 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ BLM P54132 1/20 0.39
▸ PPARG P37231 1/20 0.39
▸ ATM Q13315 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ PARP1 P09874 1/20 0.39
▸ SOS1 Q07889 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30516131 0.84 CYP2C9 (1.00) KMT2AMEN1KDM4ECYP2C9CYP3A4
SCHEMBL2583091 0.84 CYP2C9 (1.00) KMT2AMEN1KDM4ECYP2C9CYP3A4
SCHEMBL17273903 0.81 KMT2A (0.52) KMT2AMEN1KDM4ECYP2C9CYP3A4
SCHEMBL30625698 0.80 KDM4E (0.83) KMT2AMEN1KDM4ECYP2C9CYP3A4
SCHEMBL20211615 0.67 KDM4E (1.00) KMT2AMEN1KDM4EGAAMAPT
SCHEMBL20211622 0.64 MEN1 (0.58) KMT2AMEN1KDM4ECYP2C9CYP3A4
SCHEMBL30516134 0.64 MEN1 (0.58) KMT2AMEN1KDM4ECYP2C9CYP3A4
SCHEMBL22173221 0.63 MAPT (0.68) KMT2AMEN1KDM4ECYP2C9CYP3A4
SCHEMBL25835280 0.62 ERCC1 (0.50) KMT2AMEN1KDM4ECYP2C9CYP3A4
SCHEMBL15537236 0.62 MEN1 (0.58) KMT2AMEN1KDM4ECYP2C9CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9879058-B2 Use of compounds that selectively modulate astrocytic release of substances through hemichannels of connexins and pannexins, without influencing gap junctions, for the treatment of psychiatric disorders UNIVERSIDAD ANDRES BELLO (CL) 2018-01-30 — — US disclosed
US-20150337018-A1 USE OF COMPOUNDS THAT SELECTIVELY MODULATE ASTROCYTIC RELEASE OF SUBSTANCES THROUGH HEMICHANNELS OF CONNEXINS AND PANNEXINS, WITHOUT INFLUENCING GAP JUNCTIONS, FOR THE TREATMENT OF PSYCHIATRIC DISORDERS UNIVERSIDAD ANDRES BELLO (CL) 2015-11-26 — — US disclosed
Send feedback